Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers

A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers

Primary Objective:

• To determine the safety and tolerability of single and multiple ascending oral doses of CHR-5154 in healthy volunteers.

Secondary Objectives:

• To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.
• To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.

Study Overview

• Status: Terminated
• Conditions: Arthritis, Rheumatoid
• Intervention / Treatment: Drug: Placebo; Drug: CHR-5154

• Study Type: Interventional
• Enrollment (Actual): 64
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Belfast, United Kingdom, BT2 7BA
    • GSK Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Healthy male volunteers aged 18-45.
2. Non-smokers from at least three months before receiving the first dose of study drug and for the duration of the study.
3. Body mass index (BMI) ≥ 18 and ≤ 32 kg/m2.
4. Body weight ≥ 50 kg and ≤ 120 kg at screening.
5. Able to voluntarily provide written informed consent to participate in the study.
6. Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol, as confirmed during the informed consent process.
7. Sexually active male volunteers must use two highly effective methods of contraception with their partners throughout the study and for 90 days after completion of the study.
8. Male volunteers must not donate sperm during the study and for 90 days after completion of the study.
9. Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
10. The volunteer's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical study

Exclusion Criteria:

1. Volunteers with history or presence of significant cardiovascular disease, pulmonary, hepatic, gallbladder or biliary tract, renal, haematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric disease or current infection.
2. Laboratory values at screening or baseline which are deemed to be clinically significant.
3. QTcF greater than 450 msec at screening.
4. Positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
5. Current or history of drug or alcohol abuse or a positive drugs of abuse or alcohol test at screening or check-in.
6. Participation in a clinical drug study during the 90 days preceding the initial dose in this study.
7. Any clinically significant illness within 30 days prior to study drug administration.
8. Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol.
9. Volunteers who have a history or presence of any significant drug allergy.
10. Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 30 days prior to study drug administration until the end of the study, with the exception of occasional paracetamol approved by the Investigator.
11. Strenuous exercise, as judged by the Investigator, within 72 hours prior to screening, within 72 hours prior to study drug administration and for the duration of the study until after the post-study medical.
12. Weekly alcohol intake exceeding the equivalent of 21 units per week.
13. Consumption of alcoholic beverages within 24 hours prior to study drug administration and during study confinement.
14. Consumption of caffeine or xanthine-containing products within 24 hours prior to confinement and during study confinement.
15. Consumption of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade or other products containing grapefruit or Seville oranges within 7 days prior to confinement and during study confinement.
16. Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo
Experimental: CHR-5154	Drug: CHR-5154; CHR-5154

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of volunteers with adverse events	upto 10 days in Single ascending dose phase and 16 days in the Multiple ascending dose phase

Secondary Outcome Measures

Outcome Measure	Time Frame
To determine the pharmacokinetic profile of CHR-5154 and its metabolite CHR-5426.	upto 48 hrs post dose
To compare the pharmacokinetic profile of CHR-5154 and CHR-5426 after a single dose of CHR-5154 in the fed and fasted state.	Upto 48 hours

Collaborators and Investigators

• Sponsor: GlaxoSmithKline

Study record dates

Study Major Dates

• Study Start (Actual): August 12, 2013
• Primary Completion (Actual): May 28, 2014
• Study Completion (Actual): May 28, 2014

Study Registration Dates

• First Submitted: July 15, 2013
• First Submitted That Met QC Criteria: August 29, 2013
• First Posted (Estimate): September 4, 2013

Study Record Updates

• Last Update Posted (Actual): May 15, 2017
• Last Update Submitted That Met QC Criteria: May 12, 2017
• Last Verified: May 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Autoimmune Diseases; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Connective Tissue Diseases; Arthritis; Arthritis, Rheumatoid
• Other Study ID Numbers: 201302